Multiplatform web app (My Way Up) plus motivational interviewing for improving treatment retention in patients with onset of alcohol-related liver disease and alcohol use disorder - an example of participatory research.

Background: With the aim of improving treatment retention in patients with the onset of alcohol-related liver disease (ArLD), we designed a blended intervention (brief motivational intervention + 'serious game' (SG)). We present the participatory design methodology and outcomes and the usability assessment of the intervention. Methods: (1) The design of the SG was based on the outcomes of two 3-h co-creation sessions with 37 participants (healthcare and technology professionals, patients, and patients' relatives). The brief face-to-face motivational intervention was based on the 5 As Model and adapted to the ArLD population. (2) Usability pilot study: 20 participants (10 ArLD patients + 10 healthcare professionals) received the intervention. System Usability Scale (SUS) and Post-Study System Usability Questionnaire (PSSUQ) were applied to assess the SG usability and patients' satisfaction with it. Weekly semi-structured interviews on the phone were conducted to identify the preferred elements in the SG and those aspects that should be improved. Results: (1) Design: an SG in the form of a gamified web app, consisting of a daily activity for six weeks and adapted brief motivational interviewing. (2) Usability pilot study: usability results were excellent for both patients and healthcare professionals (SUS median score = 85). The general usability, the quality of the information provided by the SG and the quality of the interface were very positively rated in the PSSUQ (overall median score = 2, IQR = 1-2). The best-rated aspects were the provision of feedback, the use of metaphors and the application of audiovisual material. Changes in the design, response mechanics and content were applied after the study. Conclusions: The usability and acceptability of an intervention for increasing retention to treatment in patients with recent onset of ArLD and AUD were excellent for patients and healthcare professionals. A randomized-controlled trial is required to test the efficacy of this approach.

Destination Matters More: Relapse following Hospital-Based Treatment of Substance Use Disorders With and Without Co-Occurring Disorders.

OBJECTIVES: Addressing substance use in psychiatric care encounters significant barriers, but the emergence of specialized services offers an opportunity to advance and scale up the integration of addiction services within psychiatric settings. However, research gaps still exist in this field, particularly in understanding the substance relapse rates of people with co-occurring disorders after a psychiatric hospitalization. This study aimed to investigate and compare the relapse rates of patients under inpatient care with exclusively addiction-related issues and those with co-occurring disorders after a hospitalization in a psychiatric ward and gain insights into differences in outcomes for these two patient groups. METHODS: This retrospective analysis examined electronic medical records of patients admitted to the Acute Psychiatry Ward of the Hospital Clinic of Barcelona with a substance use disorder diagnosis between January 2019 and February 2021. Cox regression was used to identify variables independently associated with the first relapse episode. RESULTS: From a total of 318 admissions (79.2% with psychiatric comorbidity), 76.1% relapsed during the study follow-up, with a median survival time of 54 days. Younger age, female gender, voluntary admission, and outpatient follow-up were independently associated with relapse. The presence of a co-occurring disorder was not associated with relapse. CONCLUSION: This study highlights the need for interventions aimed at improving post-discharge abstinence rates for addiction-related hospitalizations. It also challenges the notion that co-occurring disorders automatically imply a worsened prognosis and emphasizes the importance of addressing addiction and psychiatric comorbidity in a comprehensive, integrated, and specialized manner.

Multifamily therapy in the community mental health network: A pragmatic randomized and controlled study.

Multifamily therapy (MFT) is a psychotherapeutic group intervention for patients with severe mental disorders (SMDs) and their families. The present study is a multicenter, randomized, and controlled trial that analyzes the benefit of MFT during outpatient treatment. The recruited patients were randomly assigned to the experimental group (n = 26), which received 24 MFT sessions in addition to their treatment as usual (TAU), or to the control group (n = 29), which received only TAU (individual and family sessions). Six months after the inclusion in the MFT, the experimental group showed a significant decrease in number of visits to the psychiatric emergency services, number of psychiatric admissions, and the days of admission. The need for hospital care 6 months after recruitment was also lower in the experimental group compared to the control group. These results suggest that the implementation of MFT during outpatient treatment facilitates community management of people diagnosed with mental health problems.

Validation of the Alcohol Smoking and Substance Involvement Screening Test (ASSIST) in acute psychiatric inpatients. / Validación de la prueba de detección de consumo de alcohol, tabaco y sustancias (ASSIST) en pacientes con trastorno psiquiátrico ingresados en una unidad de agudos.

The aims of this study were to examine the psychometric properties of The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in psychiatric inpatients, due to the scarcity of screening instruments validated in this population. Patients from Hospital Clínic's psychiatric ward (n = 202) completed: ASSIST, Addiction Severity Index (ASI), MINI-International Neuropsychiatric Interview (MINI), Alcohol Use Disorders Identification Test (AUDIT), Fagerström Test for Nicotine Dependence (FTND), Severity of Dependence Scale (SDS), and Drug Abuse Screening Test (DAST). Reliability and validity evidences based on internal structure (Exploratory and Confirmatory Factor Analyses) and on the relation to other variables were obtained. Excellent internal consistency was found for Total Substance Involvement (TSI) (α = .92 and ω = .93) and for Specific Substance Involvement (SSI) scores (α = .88 - .96 and ω = .89 - .95). Analysis of internal structure for tobacco, alcohol and cannabis subscales resulted in unidimensional models with adequate goodness-of-fit indices. ASSIST scores were significantly correlated with those of ASI (r = .795 to r = .953), AUDIT (r = .864), FTND (r = .808), DAST (r = .831), SDS (r = .519) and with "number of diagnoses of abuse/dependence" in MINI-Plus (TSI: r = .857 to r = .862; SSI: r = .646 to r = .834). Receiver operating characteristic analysis (ROC) and Mann-Whitney's U test found good discriminative validity evidences. ASSIST scores showed good reliability and there were validity evidences that support its use for identifying risk levels of tobacco, alcohol and other substance use in psychiatric patients.

Los objetivos fueron examinar las propiedades psicométricas de la prueba de detección de consumo de alcohol, tabaco y sustancias (ASSIST) en pacientes con trastorno psiquiátrico. Un total de 202 pacientes ingresados en psiquiatría del Hospital Clínic completaron: ASSIST, Índice de gravedad de la adicción (ASI), MINI-Entrevista Neuropsiquiátrica Internacional (MINI), cuestionario de identificación de los trastornos debidos al consumo de alcohol (AUDIT), Test de Fagerström (FTND), Escala de gravedad de la dependencia (SDS) y Prueba de detección de abuso de drogas (DAST). Se obtuvieron la fiabilidad y evidencia de validez de la estructura interna (análisis factorial exploratorio/confirmatorio) y de la relación con otras variables. Se encontró excelente consistencia interna en puntuaciones de riesgo total (TSI) (α = ,92 y ω = ,93) y de cada sustancia (SSI) (α = ,88 - ,96 y ω = ,89 - ,95). La estructura interna de tabaco, alcohol y cannabis resultó en modelos unidimensionales con índices de bondad de ajuste adecuados. Las puntuaciones del ASSIST correlacionaron significativamente con: ASI (r = ,795 a r = ,953), AUDIT (r = ,864), FTND (r = ,808), DAST (r = ,831), SDS (r = ,519) y «número de diagnósticos de abuso/dependencia¼ en MINI-Plus (TSI: r = ,857 - ,862; SSI: r = ,646 - ,834). El análisis de curva ROC y U de Mann-Whitney mostraron evidencias de validez discriminativa. Las puntuaciones del ASSIST tienen buena fiabilidad y existen evidencias de validez para su uso en la detección del nivel de riesgo de consumo de tabaco, alcohol y sustancias en pacientes con trastorno psiquiátrico.

Supporting Future Cannabis Policy - Developing a Standard Joint Unit: A Brief Back-Casting Exercise.

The standardization of cannabis doses is a priority for research, policy-making, clinical and harm-reduction interventions and consumer security. Scientists have called for standard units of dosing for cannabis, similar to those used for alcohol. A Standard Joint Unit (SJU) would facilitate preventive and intervention models in ways similar to the Standard Drink (SD). Learning from the SD experiences allows researchers to tackle emerging barriers to the SJU by applying modern forecasting methods. During a workshop at the Lisbon Addictions Conference 2019, a back-casting foresight method was used to address challenges and achieve consensus in developing an SJU. Thirty-two professionals from 13 countries and 10 disciplines participated. Descriptive analysis of the workshop was carried out by the organizers and shared with the participants in order to suggest amendments. Several characteristics of the SJU were defined: (1) core values: easy-to use, universal, focused on THC, accurate, and accessible; (2) key challenges: sudden changes in patterns of use, heterogeneity of cannabis compounds as well as in administration routes, variations over time in THC concentrations, and of laws that regulate the legal status of recreational and medical cannabis use); and (3) facilitators: previous experience with standardized measurements, funding opportunities, multi-stakeholder support, high prevalence of cannabis users, and widespread changes in legislation. Participants also identified three initial steps for the implementation of a SJU by 2030: (1) Building a task-force to develop a consensus-based SJU; (2) Expanded available national-level data; (3) Linking SJU consumption to the concept of "risky use," based on evidence of harms.

Motor Adaptation Impairment in Chronic Cannabis Users Assessed by a Visuomotor Rotation Task.

Background-The cerebellum has been recently suggested as an important player in the addiction brain circuit. Cannabis is one of the most used drugs worldwide, and its long-term effects on the central nervous system are not fully understood. No valid clinical evaluations of cannabis impact on the brain are available today. The cerebellum is expected to be one of the brain structures that are highly affected by prolonged exposure to cannabis, due to its high density in endocannabinoid receptors. We aim to use a motor adaptation paradigm to indirectly assess cerebellar function in chronic cannabis users (CCUs). Methods-We used a visuomotor rotation (VMR) task that probes a putatively-cerebellar implicit motor adaptation process together with the learning and execution of an explicit aiming rule. We conducted a case-control study, recruiting 18 CCUs and 18 age-matched healthy controls. Our main measure was the angular aiming error. Results-Our results show that CCUs have impaired implicit motor adaptation, as they showed a smaller rate of adaptation compared with healthy controls (drift rate: 19.3 +/- 6.8° vs. 27.4 +/- 11.6°; t(26) = -2.1, p = 0.048, Cohen's d = -0.8, 95% CI = (-1.7, -0.15)). Conclusions-We suggest that a visuomotor rotation task might be the first step towards developing a useful tool for the detection of alterations in implicit learning among cannabis users.

Patterns of alcohol, tobacco, and illicit drug use among transsexuals. / Patrones de consumo de alcohol, tabaco y drogas ilegales en personas transexuales.

This study evaluated the patterns of substance use in a large sample of male-to-female (MtoF) and female-to-male (FtoM) transsexuals. A total of 251 transsexual subjects (163 MtoF and 88 FtoM), attended in the Catalonia Gender Unit, completed self-administrated questionnaires on consumption of alcohol, tobacco, cannabis, cocaine, opioids, and designer drugs. Results were compared with the general population in Catalonia using data from the National Health Service (EDADES 2013 study). Current consumption of alcohol (70.1%), tobacco (46.2%), and cannabis (16.3%) among transsexuals was similar when compared with men (72.1%, 42.1%, 12.8%) and increased when compared with women (57.6%, 35.2%, 5%); the consumption between MtoF and FtoM subgroups was similar.  The use of cocaine was almost ten times more prevalent in the MtoF subgroup than in the FtoM subgroup (1.1%), and in general population (less than 1%).  Only a few reported uses of opioids and designer drugs. In conclusion, the substance use among transsexuals, except for the use of cocaine, was similar between MtoF and FtoM subgroups, and resembled the consumption prevalence among men in the general population. The proportion of cocaine consumers in the MtoF subgroup was up to ten times higher than in other subgroups.

Este estudio evalúa los patrones de consumo de sustancias en personas transexuales de hombre a mujer (H-M) y de mujer a hombre (M-H). Un total de 251 personas transexuales (163 H-M y 88 M-H), atendidas en la Unidad de Identidad de Género de Cataluña, completaron un cuestionario autoadministrado sobre el consumo de alcohol, tabaco, cannabis, cocaína, opiáceos y drogas de diseño. Los resultados se compararon con datos del Servicio Nacional de Salud en población general en Cataluña (estudio EDADES 2013). La prevalencia del consumo de alcohol (70,1%), tabaco (46,2%) y cannabis (16,3%) actual en el total de personas transexuales de ambos sexos fue similar al de hombres en población general (72,1%, 42,1%, 12,8%) y mayor que la prevalencia en mujeres (57,6%, 35,2%, 5%); no se encontraron diferencias en dicho consumo entre H-M y M-H. El consumo de cocaína en H-M (9,8%) fue casi diez veces más prevalente que en el subgrupo M-H (1,1%) y que en ambos sexos en población general (menor del 1%). Sólo unos pocos referían consumo de opiáceos y drogas de diseño. En conclusión, el patrón de consumo de sustancias en personas transexuales, excepto para la cocaína, es similar entre ambos sexos, y se asemeja al patrón de consumo masculino en población general. El consumo de cocaína es hasta diez veces mayor en el grupo de mujeres transexuales (H-M) con respecto a los otros grupos.

Post-truth Cannabis use: back to evidence-based medicine. / Posverdad del consumo de cannabis: de regreso a la medicina basada en la evidencia.

Editorial.

Editorial.

"Diazepam loading": ¿Can a strategy for preventing alcohol withdrawal be used to treat benzodiazepine use disorder? / "Carga de diazepam": ¿puede una estrategia para prevenir abstinencia al alcohol usarse con éxito para tratar la dependencia a benzodiacepinas?

Benzodiazepines (BZDs) are central nervous system (CNS) depressants which are widely used to treat insomnia and anxiety, despite having long-term adverse side effects. (Fortea González, Oriolo, Balcells Oliveró, Sánchez Del Valle & Castellvi, 2017). As with alcohol, continued use can lead to tolerance and dependence phenomena. Discontinuation in such cases can produce abstinence symptoms such as tremors, anxiety, seizures and, occasionally, death (Brett y Murnion, 2015).

Las benzodiacepinas se usan para tratar la abstinencia alcohólica siguiendo varias estrategias: dosis descendiente, dosis de carga, tratamiento en función de sintomatología. La carga de diazepam ha demostrado ser un tratamiento válido para la abstinencia alcohólica en ensayos controlados aleatorizados. Tras una búsqueda bibliográfica no sistemática, no hemos encontrado antecedentes en la literatura de una estrategia de carga de diazepam sin posterior administración de benzodiacepinas para el tratamiento de la abstinencia a éstas. Describimos el caso de una desintoxicación de benzodiacepinas utilizando una situación preestablecida de carga de diazepam. La paciente tenía una larga historia de dependencia a benzodiazepinas que se había tratado previamente con escaso éxito con dosis descendiente de clonazepam. El día anterior al ingreso hospitalario, realizó sobreingesta de unos 200 mg de diazepam con finalidad suicida. Se decidió utilizar una estrategia de carga de diazepam para tratar el síndrome abstinencial. Así, no se administraron posteriores dosis de benzodiacepinas, considerando la sobreingesta de 200 mg de diazepam como dosis de carga única. En esta experiencia, la carga de diazepam resultó ser una estrategia válida y rápida para tratar una dependencia a las benzodiacepinas resistente. Los trastornos por uso de benzodiacepinas son un relevante problema de salud pública, en contraste con los escasos avances obtenidos en su tratamiento. Tal vez valdría la pena empezar por revisar y actualizar antiguas estrategias.

[High prevalence of cannabinoid hyperemesis syndrome in marijuana users]. / Elevada prevalencia del síndrome de hiperémesis cannábica en pacientes consumidores de cánnabis.

OBJECTIVES: Cannabinoid hyperemesis syndrome (CHS) is a recently described condition associated with chronic marijuana use. CHS is defined by the triad of chronic marijuana consumption cyclic bouts of nausea and vomiting, plus frequent hot showering. Its etiology, pathogenesis, and epidemiology remain obscure. We interviewed all patients over the age of 18 years attended between February and April 2014 in an outpatient marijuana rehabilitation center. A questionnaire was used to collect sociodemographic and clinical data as well as information related to a diagnosis of CHS. Of 22 patients who met the inclusion criteria, 4 (18.2%) reported symptoms suggestive of CHS; 2 (9.1%) had all symptoms, and 2 (9.1%) had some. CHS is common. We recommend asking about symptoms that might indicate this diagnosis given that CHS generates a high level of discomfort as well as diagnostic errors and many referrals to specialists.

OBJETIVO: El síndrome de hiperémesis cannábica (SHC) es una triada consistente en uso crónico de cánnabis, náuseas y vómitos, y duchas de agua caliente de presentación cíclica asociada al consumo crónico de cánnabis. Es una patología descrita recientemente con una etiopatogenia y epidemiología desconocidas. Se entrevistó todos los pacientes mayores de 18 años atendidos desde febrero a abril de 2014 en una consulta ambulatoria para deshabituación del cánnabis. Se diseñó un cuestionario para recoger datos sociodemográficos, clínicos y criterios diagnósticos de SHC. De los 22 pacientes que cumplieron los criterios de inclusión, un 18,2% (n = 4) refirieron haber presentado síntomas sugestivos de SHC, de una forma parcial [9,1% (n = 2)] o completa [9,1% (n = 2)]. El SHC es una entidad frecuente, por lo que recomendamos preguntar por la presencia de clínica sugestiva dado que genera un el elevado grado de disconfort, errores diagnósticos y múltiples consultas a especialistas.